2月18日 - ** CSL CSL.AX 股价上涨 1.5% 至 153.78 澳元
** (link) 上半年利润下降81%，首席执行官保罗-麦肯齐（Paul McKenzie）下台，股价在上周暴跌16.9%后反弹
** 澳大利亚生物技术巨头与礼来公司LLY.N签署了 (link) 许可协议，授予其开发和商业化克拉唑珠单抗的某些权利
** Clazakizumab是一种抗体，旨在预防终末期肾病患者与心脏有关的疾病和死亡
** CSL 将获得 1 亿美元的预付款
** CSL 股价今年以来下跌了 10.9%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.